Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial

समान संसाधन

• Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies
  द्वारा: Merkies, Ingemar S.J., और अन्य
  प्रकाशित: (2019)
• Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)
  द्वारा: Léger, Jean-Marc, और अन्य
  प्रकाशित: (2013)
• Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study
  द्वारा: van Schaik, Ivo N., और अन्य
  प्रकाशित: (2019)
• Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions
  द्वारा: Gingele, Stefan, और अन्य
  प्रकाशित: (2021)
• Deregulated Fcγ receptor expression in patients with CIDP
  द्वारा: Quast, Isaak, और अन्य
  प्रकाशित: (2015)